Denis Patrick
Private Equity Investor at PFIZER, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jim Broderick | M | 55 |
Palleon Pharmaceuticals, Inc.
 Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | 9 years |
| Albert Bourla | M | 62 | 31 years | |
| Stephen Worland | M | 66 |
eFFECTOR Therapeutics Operations, Inc.
 eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | 12 years |
| Sue Desmond-Hellmann | M | 66 | 4 years | |
| Frank G. Haluska | M | 64 |
Kestrel Therapeutics, Inc.
 Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kestrel Therapeutics, Inc. is a company that has two habitat restoration projects aimed at helping native animals that are at risk, specifically the American Kestrel and the Eastern Spadefoot Toad. The company is based in Wayland, MA. The company's mission is to conserve and care for forests, farms, and riverways of the Pioneer Valley while nurturing an enduring love of the land. The CEO of the company is Frank G. Haluska. | - |
| Douglas Lankler | M | 58 | 25 years | |
| Colin Goddard | M | 64 |
FoRx Therapeutics AG
 FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland.
MISSION Therapeutics Ltd.
 MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 9 years |
| Margaret M. Madden | F | - | - | |
| Michael Baran | M | - |
Pfizer Venture Investments LLC
 Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 16 years |
| James Quincey | M | 59 | 4 years | |
| Sally Susman | F | 62 | 17 years | |
| Stephen Philip Jackson | M | - |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 13 years |
| Dan Littman | M | 71 | 6 years | |
| Rady Johnson | M | 63 | 30 years | |
| James B. Summers | M | - |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 5 years |
| David Johnson | M | 59 |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | 3 years |
| Eyal Gottlieb | M | - |
Metabomed Ltd.
 Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | 11 years |
| Helen Hobbs | M | 71 | 13 years | |
| Christopher O’Donnell | M | 55 |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 6 years |
| Rana Al-Hallaq | M | - |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 6 years |
| Thanos Halazonetis | M | - |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland. | 5 years |
| Sotirios K. Sotiriou | M | - |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland. | 5 years |
| John Hennessy | M | - |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | - |
| Hugo Beekman | M | - |
Evolveimmune Therapeutics, Inc.
 Evolveimmune Therapeutics, Inc. BiotechnologyHealth Technology EvolveImmune Therapeutics Inc. engages in the provision of healthcare services. It offers immunotherapy platform to develop molecules for the treatment of oncology and immune diseases. The company was founded in 2019 and is headquartered in Westport, CT. | - |
| Alessandra di Bacco | F | - |
Evolveimmune Therapeutics, Inc.
Evolveimmune Therapeutics, Inc. BiotechnologyHealth Technology EvolveImmune Therapeutics Inc. engages in the provision of healthcare services. It offers immunotherapy platform to develop molecules for the treatment of oncology and immune diseases. The company was founded in 2019 and is headquartered in Westport, CT. | - |
| Alana McNulty | F | 61 |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | 12 years |
| Joseph Echevarria | M | 66 | 9 years | |
| Jim Smith | M | 64 | 10 years | |
| Deepa Pakianathan | M | 59 |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | 4 years |
| Shantanu Narayen | M | 60 | 11 years | |
| Barbara Dalton | M | 69 |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 17 years |
| Ronald Blaylock | M | 64 | 7 years | |
| Stephen Bloch | M | 62 |
Evolveimmune Therapeutics, Inc.
Evolveimmune Therapeutics, Inc. BiotechnologyHealth Technology EvolveImmune Therapeutics Inc. engages in the provision of healthcare services. It offers immunotherapy platform to develop molecules for the treatment of oncology and immune diseases. The company was founded in 2019 and is headquartered in Westport, CT. | 4 years |
| Anker Gunvald Lundemose | M | 63 |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | - |
| Susan Hockfield | M | 73 | 4 years | |
| Suzanne Johnson | F | 66 | 17 years | |
| Michael G. Moore | M | - |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 12 years |
| Scott Gottlieb | M | 51 | 5 years | |
| Aamir Malik | M | 48 | 3 years | |
| Steve Danehy | M | - | 12 years | |
| Patrice Ettinger | F | - | - | |
| Alexandre de Germay | M | - | 1 years | |
| Aida Habtezion | M | - | 3 years | |
| Mike McDermott | M | 58 | 21 years | |
| Bryan Supran | M | - | 8 years | |
| Jerica Pitts | F | - | 3 years | |
| Markus Green | M | - | 18 years | |
| Annaliesa Anderson | M | - | 17 years | |
| Avery Waite | F | - | 1 years | |
| John DeYoung | M | 61 | 33 years | |
| Maria Gabriella Camboni | M | 66 |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | - |
| Chris Boshoff | M | - | - | |
| David Denton | M | 59 | 2 years | |
| Mikael Dolsten | M | 65 | 15 years | |
| Bobby G. Soni | M | 53 |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | - |
| Ronen Tamir | M | 57 | 5 years | |
| Deborah Harland | M | 64 |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | - |
| Graziano Seghezzi | M | 55 |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | - |
| Lidia Fonseca | F | 55 | - | |
| Karan Takhar | M | 32 |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | - |
| Elizabeth E. Bailey | F | 86 |
University of Pennsylvania
| 33 years |
| Elaine Jones | M | 69 |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | - |
| Suneet Varma | M | 55 | 23 years | |
| Rajeev Dadoo | M | 54 |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | - |
| Jayson Punwani | M | - |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | - |
| Lori Hu | F | 38 |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | 6 years |
| Maria Rivas | M | 60 | 2 years | |
| Jonathan Hepple | M | 53 |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 3 years |
| Aaron Foster | M | - | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ian Read | M | 71 | 41 years | |
| Jeffrey Kindler | M | 68 | 8 years | |
| William Steere | M | 87 | 28 years | |
| David Vurgait | M | 59 |
University of Pennsylvania
| 1 years |
| Amy Schulman | F | 63 | 6 years | |
| George A. Lorch | M | 82 | 15 years | |
| Dennis Ausiello | M | 78 | 13 years | |
| Alex Abell | M | - |
University of Pennsylvania
| 4 years |
| Olivier Brandicourt | M | 68 | 13 years | |
| Robert Landry | M | 60 | 4 years | |
| John Mascotte | M | 84 | 4 years | |
| Everett Cunningham | M | 57 | 9 years | |
| Jonathan Emms | M | - | 20 years | |
| Gregory Z. Rush | M | - |
University of Pennsylvania
| 4 years |
| Yi Ning Zhao | M | 53 | 8 years | |
| Jennifer Schroeder | F | - | 20 years | |
| Joseph Arena | M | 69 | 3 years | |
| Sassan Alizadeh | M | - |
University of Pennsylvania
| 7 years |
| Stephen W. Sanger | M | 78 | 9 years | |
| Mace Rothenberg | M | 67 | 13 years | |
| Frank D'Amelio | M | 66 | 14 years | |
| Michael Brown | M | 82 | 16 years | |
| M. Anthony Burns | M | 81 | 25 years | |
| William Herbert Gray | M | 82 | 13 years | |
| Robert N. Burt | M | 86 | 11 years | |
| James Kilts | M | 76 | 13 years | |
| Wyllie Cornwell | M | 76 | 23 years | |
| Frances Fergusson | M | 79 | 9 years | |
| Charles H. Hill | M | 69 | 31 years | |
| Freda Lewis-Hall | M | 69 | 11 years | |
| Lori McNeill | F | 51 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 86 | 86.00% |
| United Kingdom | 11 | 11.00% |
| Switzerland | 3 | 3.00% |
| Israel | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Denis Patrick
- Personal Network
